title: Synthetic protocol published for promising anticancer compound.
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy; D002384:Catalysis; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D007536:Isomerism; D009369:Neoplasms / Q000188:drug therapy; D009999:Ossification, Heterotopic / Q000628:therapy; D010879:Piperazines / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D018168:Receptors, Retinoic Acid / Q000819:agonists / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors / Q000378:metabolism; D056811:Unfolded Protein Response; D000097768:Retinoic Acid Receptor gamma
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D010879:Piperazines; D051736:Proto-Oncogene Proteins c-mdm2; D018168:Receptors, Retinoic Acid; D016159:Tumor Suppressor Protein p53; D000097768:Retinoic Acid Receptor gamma; C482205:nutlin 3